2024

• Jiang, X., Hoffmeister, M., Brenner, H., Muti, H., Yuan, T., Foersch, S., West, N., Brobeil, A., Jonnagaddala, J., Ward, R., et al (2024). End-to-end prognostication in colorectal cancer by deep learning: a retrospective, multicentre study. The Lancet Digital Health, 6(1), e33-e43. [More Information]
• Shingleton, J., Stapleton, B., Kelly, A., Ward, R., Lean, C., Rushton, S., O'Brien, T. (2024). eviQ Cancer Treatments Online: Providing evidence-based information to improve cancer patient outcomes. Asia-Pacific Journal of Clinical Oncology, 20(4), 491-496. [More Information]

2023

• Stark, Z., Boughtwood, T., Haas, M., Braithwaite, J., Gaff, C., Goranitis, I., Spurdle, A., Hansen, D., Hofmann, O., Laing, N., Newson, A., Ward, R., et al (2023). Australian Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in healthcare. American Journal of Human Genetics, 110(3), 419-426. [More Information]
• Yap, S., He, E., Egger, S., Goldsbury, D., Lew, J., Ngo, P., Worthington, J., Rillstone, H., Zalcberg, J., Cuff, J., Ward, R., Canfell, K., Feletto, E., Steinberg, J. (2023). Colon and rectal cancer treatment patterns and their associations with clinical, sociodemographic and lifestyle characteristics: analysis of the Australian 45 and Up Study cohort. BMC Cancer, 23(1). [More Information]
• Ward, R., Nutbeam, D., Mijnhardt, W., Nelson, P., Todd, B., Rees, M., Richards, J., Khan, N., Chung, S. (2023). Development of a novel and more holistic approach for assessing impact in health and medical research: the Research Impact Assessment Framework. Australian Health Review, 47(5), 589-595. [More Information]
• Mouradov, D., Greenfield, P., Li, S., In, E., Storey, C., Sakthianandeswaren, A., Georgeson, P., Buchanan, D., Ward, R., Hawkins, N., et al (2023). Oncomicrobial Community Profiling Identifies Clinicomolecular and Prognostic Subtypes of Colorectal Cancer. Gastroenterology, 165(1), 104-120. [More Information]
• Wagner, S., Reisenbüchler, D., West, N., Niehues, J., Zhu, J., Foersch, S., Veldhuizen, G., Quirke, P., Grabsch, H., van den Brandt, P., Ward, R., et al (2023). Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study. Cancer Cell, 41(9), 1650-1661.e4. [More Information]

2022

• Morrell, S., Kohonen-Corish, M., Ward, R., Sorrell, T., Roder, D., Currow, D. (2022). Antibiotic exposure within six months before systemic therapy was associated with lower cancer survival. Journal of Clinical Epidemiology, 147, 122-131. [More Information]
• Norris, S., Belcher, A., Jaure, A., Ward, R. (2022). Evaluating genetic and genomic tests for heritable conditions in Australia: lessons learnt from health technology assessments. Journal of Community Genetics, 13(5), 503-522. [More Information]
• Meagher, N., Gorringe, K., Wakefield, M., Bolithon, A., Pang, C., Chiu, D., Anglesio, M., Mallitt, K., Doherty, J., Harris, H., Chou, A., Gill, A., Ward, R., Anderson, L., deFazio, A., et al (2022). Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower astrointestinal tumors identifies markers associated with adverse outcomes. Clinical Cancer Research, 28(24), 5383-5395. [More Information]
• Nic Giolla Easpaig, B., Tran, Y., Winata, T., Lamprell, K., Fajardo Pulido, D., Arnolda, G., Delaney, G., Liauw, W., Smith, K., Avery, S., Ward, R., et al (2022). The complexities, coordination, culture and capacities that characterise the delivery of oncology services in the common areas of ambulatory settings. BMC Health Services Research, 22(1), 190-1-190-15. [More Information]
• Kang, Y., Caruana, M., McLoughlin, K., Killen, J., Simms, K., Taylor, N., Frayling, I., Coupe, V., Boussioutas, A., Trainer, A., Ward, R., Canfell, K., et al (2022). The predicted effect and cost-effectiveness of tailoring colonoscopic surveillance according to mismatch repair gene in patients with Lynch syndrome. Genetics in Medicine, 24(9), 1831-1846. [More Information]

2021

• Latimer, N., Pollard, D., Towse, A., Henshall, C., Sansom, L., Ward, R., Bruce, A., Deakin, C. (2021). Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi-stakeholder, international workshop. BMC Health Services Research, 21(1), 412-1-412-9. [More Information]
• Gray, J., Sullivan, T., Latimer, N., Salter, A., Sorich, M., Ward, R., Karnon, J. (2021). Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer. Medical Decision Making, 41(2), 179-193. [More Information]
• Meiser, B., Kaur, R., Morrow, A., Peate, M., Wong, W., McPike, E., Cops, E., Nichols, C., Austin, R., Fine, M., Ward, R., et al (2021). Impact of national guidelines on use of BRCA1/2 germline testing, risk management advice given to women with pathogenic BRCA1/2 variants and uptake of advice. Hereditary Cancer in Clinical Practice, 19(1), 24. [More Information]
• Tudini, E., Davidson, A., Dressel, U., Andrews, L., Antill, Y., Crook, A., Field, M., Gattas, M., Harris, R., Kirk, J., Ward, R., et al (2021). Implementing gene curation for hereditary cancer susceptibility in Australia: Achieving consensus on genes with clinical utility. Journal of Medical Genetics, 58(12), 853-858. [More Information]
• Nic Giolla Easpaig, B., Tran, Y., Winata, T., Lamprell, K., Fajardo Pulido, D., Arnolda, G., Delaney, G., Liauw, W., Smith, K., Avery, S., Westbrook, J., Olver, I., Girgis, A., Ward, R., et al (2021). Providing outpatient cancer care for CALD patients: a qualitative study. BMC Research Notes, 14(1), 304. [More Information]
• Vidgen, M., Williamson, D., Cutler, K., McCafferty, C., Ward, R., McNeil, K., Waddell, N., Bunker, D. (2021). Queensland Genomics: an adaptive approach for integrating genomics into a public healthcare system. npj Genomic Medicine, 6(1), 71. [More Information]

2020

• Ali, A., Dumbrava, M., Riddell, K., Stewart, N., Ward, R., Ibrahim, A., Chin, M. (2020). Correlation between initial tumour volume and treatment duration on Dabrafenib: Observation study of subjects with BRAF mutant melanoma on the BRF112680 trial. BMC Cancer, 20(1), 342. [More Information]
• Schaffer, A., Pearson, S., Perez-Concha, O., Dobbins, T., Ward, R., Leeuwen, M., Rhee, J., Laaksonen, M., Craigen, G., Vajdic, C. (2020). Diagnostic and health service pathways to diagnosis of cancer-registry notified cancer of unknown primary site (cup). PloS One, 15(3), e0230373. [More Information]
• Meiser, B., Kaur, R., Kirk, J., Morrow, A., Peate, M., Wong, W., McPike, E., Cops, E., Dowson, C., Austin, R., Ward, R., et al (2020). Evaluation of implementation of risk management guidelines for carriers of pathogenic variants in mismatch repair genes: a nationwide audit of familial cancer clinics. Familial Cancer, 19(4), 337-346. [More Information]
• Belcher, A., Ginsburg, G., Ward, R. (2020). Global approaches to genomic medicine implementation. Science Translational Medicine, 12(563). [More Information]
• Feletto, E., Lew, J., Worthington, J., He, E., Caruana, M., Butler, K., Hui, H., Taylor, N., Banks, E., Barclay, K., Grogan, P., Kench, J., Taoube, L., Ward, R., Armstrong, B., Canfell, K., et al (2020). Pathways to a cancer-free future: A protocol for modelled evaluations to minimise the future burden of colorectal cancer in Australia. BMJ Open, 10(6), 1-9. [More Information]
• Kang, Y., Killen, J., Caruana, M., Simms, K., Taylor, N., Frayling, I., Snowsill, T., Huxley, N., Coupe, V., Hughes, S., Ward, R., Canfell, K., et al (2020). The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome. Medical Journal of Australia, 212(2), 72-81. [More Information]
• Williams, D., Mouradov, D., Newman, M., Amini, E., Nickless, D., Fang, C., Palmieri, M., Sakthianandeswaren, A., Li, S., Ward, R., et al (2020). Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation. Modern Pathology, 33(7), 1420-1432. [More Information]
• Nic Giolla Easpaig, B., Tran, Y., Bierbaum, M., Arnolda, G., Delaney, G., Liauw, W., Ward, R., Olver, I., Currow, D., Girgis, A., et al (2020). What are the attitudes of health professionals regarding patient reported outcome measures (PROMs) in oncology practice? A mixed-method synthesis of the qualitative evidence. BMC Health Services Research, 20(1), 102. [More Information]

2019

• He, E., Alison, R., Blanks, R., Pirie, K., Reeves, G., Ward, R., Steele, R., Patnick, J., Canfell, K., Beral, V., et al (2019). Association of ten gastrointestinal and other medical conditions with positivity to faecal occult blood testing in routine screening: A large prospective study of women in England. International Journal of Epidemiology, 48(2), 549-558. [More Information]
• Vajdic, C., Perez-Concha, O., Dobbins, T., Ward, R., Schaffer, A., van Leeuwen, M., Rhee, J., Laaksonen, M., Craigen, G., Pearson, S. (2019). Demographic, social and lifestyle risk factors for cancer registry-notified cancer of unknown primary site (CUP). Cancer Epidemiology, 60, 156-161. [More Information]
• Jorissen, R., Croxford, M., Jones, I., Ward, R., Hawkins, N., Gibbs, P., Sieber, O. (2019). Evaluation of the transferability of survival calculators for stage II/III colon cancer across healthcare systems. International Journal of Cancer, 145(1), 132-142. [More Information]
• Vajdic, C., Perez-Concha, O., Rhee, J., Dobbins, T., Ward, R., Schaffer, A., van Leeuwen, M., Laaksonen, M., Craigen, G., Pearson, S. (2019). Health-related predictors of cancer registry-notified cancer of unknown primary site (CUP). Cancer Epidemiology, 61, 1-7. [More Information]
• Williams, D., Mouradov, D., Jorissen, R., Newman, M., Amini, E., Nickless, D., Teague, J., Fang, C., Palmieri, M., Parsons, M., et al (2019). Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. Gut, 68(3), 465-474. [More Information]
• Poulos, R., Perera, D., Packham, D., Shah, A., Janitz, C., Pimanda, J., Hawkins, N., Ward, R., Hesson, L., Wong, J. (2019). Scarcity of Recurrent Regulatory Driver Mutations in Colorectal Cancer Revealed by Targeted Deep Sequencing. JNCI Cancer Spectrum, 3(2), 1-8. [More Information]
• Nic Giolla Easpaig, B., Arnolda, G., Tran, Y., Bierbaum, M., Lamprell, K., Delaney, G., Liauw, W., Chittajallu, R., Winata, T., Ward, R., et al (2019). What is multidisciplinary cancer care like in practice? a protocol for a mixed-method study to characterise ambulatory oncology services in the Australian public sector. BMJ Open, 9(10), 1-10. [More Information]

2018

• Tuffaha, H., Mitchell, A., Ward, R., Connelly, L., Butler, J., Norris, S., Scuffham, P. (2018). Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers. Genetics in Medicine, 20(9), 985-994. [More Information]
• Mascarenhas, L., Shanley, S., Mitchell, G., Spurdle, A., Macrae, F., Pachter, N., Buchanan, D., Ward, R., Fox, S., Duxbury, E., et al (2018). Current mismatch repair deficiency tumor testing practices and capabilities: A survey of Australian pathology providers. Asia-Pacific Journal of Clinical Oncology, 14(6), 417-425. [More Information]
• Liu, Q., Thoms, J., Nunez, A., Huang, Y., Knezevic, K., Packham, D., Poulos, R., Williams, R., Beck, D., Hawkins, N., et al (2018). Disruption of a -35kb enhancer impairs CTCF binding and MLH1 expression in colorectal cells. Clinical Cancer Research, 24(18), 4602-4611. [More Information]
• Siu, L., Lawler, M., Haussler, D., Knoppers, B., Lewin, J., Vis, D., Liao, R., Andre, F., Banks, I., Barrett, J., et al (2018). Facilitating a culture of responsible and effective sharing of cancer genome data. In Arthur L Caplan & Barbara K Redman (Eds.), Getting to Good: Research Integrity in the Biomedical Sciences, (pp. 539-548). New York: Springer International Publishing. [More Information]
• He, E., Lew, J., Egger, S., Banks, E., Ward, R., Beral, V., Canfell, K. (2018). Factors associated with participation in colorectal cancer screening in Australia: Results from the 45 and Up Study cohort. Preventive Medicine, 106, 185-193. [More Information]
• Daniels, B., Kiely, B., Lord, S., Houssami, N., Lu, C., Ward, R., Pearson, S. (2018). Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016). Breast Cancer Research and Treatment, 171(1), 151-159. [More Information]
• Sakthianandeswaren, A., Parsons, M., Mouradov, D., MacKinnon, R., Catimel, B., Liu, S., Palmieri, M., Love, C., Jorissen, R., Li, S., et al (2018). MACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors. Cancer Discovery, 8(8), 988-1005. [More Information]
• Domingo, E., Kaisaki, P., Camps, C., Parsons, M., Mouradov, D., Pentony, M., Makino, S., Palmieri, M., Ward, R., Hawkins, N., et al (2018). Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. The Lancet Gastroenterology & Hepatology, 3(9), 635-643. [More Information]
• Tan, S., O’Neill, S., Goldstein, D., Ward, R., Daniels, B., Vajdic, C. (2018). Predictors of care for patients with cancer of unknown primary site in three Australian hospital. Asia-Pacific Journal of Clinical Oncology, 14(5), e512-e520. [More Information]
• Loke, L., Chen, T., Lewis, C., Ward, R., Rushton, S., Shapiro, J. (2018). Quality and impact of eviQ Cancer Treatments Online (www.eviq.org.au): the medical oncologist's perspective. Asia-Pacific Journal of Clinical Oncology, 14(2), e203-e210. [More Information]
• Morris, M., Hesson, L., Poulos, R., Ward, R., Wong, J., Youngson, N. (2018). Reduced nuclear DNA methylation and mitochondrial transcript changes in adenomas do not associate with mtDNA methylation. Biomarker Research, 6(37), 1-8. [More Information]
• Daniels, B., Kiely, B., Houssami, N., Lord, S., Dobbins, T., Lu, C., Ward, R., Pearson, S. (2018). Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: A national population-based observational study (2006-2014). British Journal of Cancer, 118(3), 441-447. [More Information]
• Daniels, B., Kiely, B., Lord, S., Houssami, N., Lu, C., Ward, R., Pearson, S. (2018). Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001-2016). Breast, 38, 7-13. [More Information]

2017

• Liang, R., Meiser, B., Smith, S., Kasparian, N., Lewis, C., Chin, M., Long, G., Ward, R., Menzies, A., Harris-Wai, J., et al (2017). Advanced cancer patients' attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study. European Journal of Cancer Care, 26(6), 1-11. [More Information]
• Chen, Y., Peate, M., Kaur, R., Meiser, B., Wong, T., Kirk, J., Ward, R., Goodwin, A., Macrae, F., Hiller, J., et al (2017). Exploring clinicians' attitudes about using aspirin for risk reduction in people with Lynch Syndrome with no personal diagnosis of colorectal cancer. Familial Cancer, 16(1), 99-109. [More Information]
• Doust, J., Vandvik, P., Qaseem, A., Mustafa, R., Horvath, A., Frances, A., Al-Ansary, L., Bossuyt, P., Ward, R., et al (2017). Guidance for modifying the definition of diseases: A checklist. JAMA Internal Medicine, 177(7), 1020-1025. [More Information]
• Pearce, A., Haas, M., Viney, R., Pearson, S., Haywood, P., Brown, C., Ward, R. (2017). Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study. PloS One, 12(10), 1-12. [More Information]
• Ward, R., Ginsburg, G. (2017). Local and Global Challenges in the Clinical Implementation of Precision Medicine. In Geoffrey Ginsburg, & Huntington Willard (Eds.), Genomic and Precision Medicine, (pp. 105-117). London: Elsevier. [More Information]
• Harris, C., Daniels, B., Ward, R., Pearson, S. (2017). Retrospective comparison of Australia's Pharmaceutical Benefits Scheme claims data with prescription data in HER2-positive early breast cancer patients, 2008-2012. Public Health Research and Practice, 27(5), 1-9. [More Information]
• Vis, D., Lewin, J., Liao, R., Mao, M., Andre, F., Ward, R., Calvo, F., Teh, B., Camargo, A., et al (2017). Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape. Annals of Oncology, 28(5), 1145-1151. [More Information]
• Daniels, B., Lord, S., Kiely, B., Houssami, N., Haywood, P., Lu, C., Ward, R., Pearson, S. (2017). Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: Protocol detailing observations in a whole of population cohort. BMJ Open, 7(1), 1-12. [More Information]
• Ma, S., Henry, C., Llamosas, E., Higgins, R., Daniels, B., Hesson, L., Hawkins, N., Ward, R., Ford, C. (2017). Validation of specificity of antibodies for immunohistochemistry: the case of ROR2. Virchows Archiv, 470(1), 99-108. [More Information]

2016

• Liu, Q., Hesson, L., Nunez, A., Packham, D., Williams, R., Ward, R., Sloane, M. (2016). A cryptic paracentric inversion of MSH2 exons 2-6 causes Lynch syndrome. Carcinogenesis, 37(1), 10-17. [More Information]
• Manolio, T., Ward, R., Ginsburg, G. (2016). Clinical implementation of genomic medicine: the importance of global collaboration Expert Review of Precision Medicine and Drug Development. Expert Review of Precision Medicine and Drug Development, 1(4), 349-351. [More Information]
• Sloane, M., Ward, R., Hesson, L. (2016). Defining the criteria for identifying constitutional epimutations. Clinical Epigenetics, 8(1), 39. [More Information]
• Siu, L., Lawler, M., Haussler, D., Knoppers, B., Lewin, J., Vis, D., Liao, R., Andre, F., Banks, I., Ward, R., et al (2016). Facilitating a culture of responsible and effective sharing of cancer genome data. Nature Medicine, 22(5), 464-471. [More Information]
• Schofield, P., Stockler, M., Zannino, D., Tebbutt, N., Price, T., Simes, R., Wong, N., Pavlakis, N., Ransom, D., Moylan, E., Wilcken, N., et al (2016). Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer. Supportive Care in Cancer, 24(1), 401-408. [More Information]
• Hesson, L., Ng, B., Zarzour, P., Srivastava, S., Kwok, C., Packham, D., Nunez, A., Beck, D., Ryan, R., Dower, A., Bourke, M., et al (2016). Integrated Genetic, Epigenetic, and Transcriptional Profiling Identifies Molecular Pathways in the Development of Laterally Spreading Tumors. Molecular Cancer Research, 14(12), 1217-1228. [More Information]
• Jonnagaddala, J., Croucher, J., Jue, T., Meagher, N., Caruso, L., Ward, R., Hawkins, N. (2016). Integration and analysis of heterogeneous colorectal cancer data for translational research. 13th International Conference on Nursing Informatics, NI 2016, Geneva: IOS Press. [More Information]
• Malaterre, J., Pereira, L., Putoczki, T., Millen, R., Paquet-Fifield, S., Germann, M., Liu, J., Cheasley, D., Sampurno, S., Ward, R., et al (2016). Intestinal-specific activatable Myb initiates colon tumorigenesis in mice. Oncogene, 35(19), 2475-2484. [More Information]
• Liu, Q., Hesson, L., Nunez, A., Packham, D., Hawkins, N., Ward, R., Sloane, M. (2016). Pathogenic germline MCM9 variants are rare in Australian Lynch-like syndrome patients. Cancer Genetics, 209(11), 497-500. [More Information]
• Chandrakanthan, V., Yeola, A., Kwan, J., Oliver, R., Qiao, Q., Kang, Y., Zarzour, P., Beck, D., Boelen, L., Unnikrishnan, A., et al (2016). Pdgf-ab and 5-Azacytidine induce conversion of somatic cells into tissue-regenerative multipotent stem cells. Proceedings of the National Academy of Sciences of the United States of America, 113(16), E2306-E2315. [More Information]
• Suraweera, N., Mouradov, D., Li, S., Jorissen, R., Hampson, D., Ghosh, A., Sengupta, N., Thaha, M., Ahmed, S., Ward, R., et al (2016). Relative telomere lengths in tumor and normal mucosa are related to disease progression and chromosome instability profiles in colorectal cancer. Oncotarget, 7(24), 36474-36488. [More Information]
• Ma, S., Srivastava, S., Llamosas, E., Hawkins, N., Hesson, L., Ward, R., Ford, C. (2016). ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration. BMC Cancer, 16(1), 508. [More Information]
• Kuroiwa-Trzmielina, J., Wang, F., Rapkins, R., Ward, R., Buchanan, D., Win, A., Clendenning, M., Rosty, C., Southey, M. (2016). SNP rs16906252C>T is an expression and methylation quantitative trait locus associated with an increased risk of developing MGMT-methylated colorectal cancer. Clinical Cancer Research, 22(24), 6266-6277. [More Information]
• He, E., Hawkins, N., Mak, G., Roncolato, F., Goldstein, D., Liauw, W., Clingan, P., Chin, M., Ward, R. (2016). The impact of mismatch repair status in colorectal cancer on the decision to treat with adjuvant chemotherapy: An Australian population-based multicenter study. The Oncologist, 21(5), 618-625. [More Information]
• He, E., Wyld, L., Sloane, M., Canfell, K., Ward, R. (2016). The molecular characteristics of colonic neoplasms in serrated polyposis: a systematic review and meta-analysis. The Journal of Pathology: Clinical Research, 2(3), 127-137. [More Information]
• Henshall, C., Sansom, L., Latimer, N., Ward, R. (2016). Treatment switching in cancer trials: Issues and proposals. International Journal of Technology Assessment in Health Care, 32(3), 167-174. [More Information]
• Liu, Q., Thompson, B., Ward, R., Hesson, L., Sloane, M. (2016). Understanding the Pathogenicity of Noncoding Mismatch Repair Gene Promoter Variants in Lynch Syndrome. Human Mutation, 37(5), 417-426. [More Information]

2015

• Pearce, A., Haas, M., Viney, R., Haywood, P., Pearson, S., Van Gool, K., Srasuebkul, P., Ward, R. (2015). Can administrative data be used to measure chemotherapy side effects? Expert Review of Pharmacoeconomics and Outcomes Research, 15(2), 215-222. [More Information]
• Ward, R., Laaksonen, M., Van Gool, K., Pearson, S., Daniels, B., Bastick, P., Norman, R., Hou, C., Haywood, P., Haas, M. (2015). Cost of cancer care for patients undergoing chemotherapy: The Elements of Cancer Care study. Asia-Pacific Journal of Clinical Oncology, 11(2), 178-186. [More Information]
• Frederix, G., Afzali, H., Dasbach, E., Ward, R. (2015). Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions. PharmacoEconomics, 33(8), 777-781. [More Information]
• Henry, C., Quadir, A., Hawkins, N., Jary, E., Llamosas, E., Kumar, D., Daniels, B., Ward, R., Ford, C. (2015). Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both ?-catenin dependent and independent Wnt signalling. Journal of Cancer Research and Clinical Oncology, 141(2), 243-254. [More Information]
• Manolio, T., Abramowicz, M., Al-Mulla, F., Anderson, W., Balling, R., Berger, A., Bley, S., Chakravarti, A., Chantratita, W., Ward, R., et al (2015). Global implementation of genomic medicine: We are not alone. Science Translational Medicine, 7(290). [More Information]
• Vajdic, C., Schaffer, A., Dobbins, T., Ward, R., Er, C., Pearson, S. (2015). Health service utilisation and investigations before diagnosis of cancer of unknown primary (CUP): A population-based nested case-control study in Australian Government Department of Veterans' Affairs clients. Cancer Epidemiology, 39(4), 585-592. [More Information]
• Hesson, L., Packham, D., Kwok, C., Nunez, A., Ng, B., Schmidt, C., Fields, M., Wong, J., Sloane, M., Ward, R. (2015). Lynch Syndrome Associated with Two MLH1 Promoter Variants and Allelic Imbalance of MLH1 Expression. Human Mutation, 36(6), 622-630. [More Information]
• Sloane, M., Nunez, A., Packham, D., Kwok, C., Suthers, G., Hesson, L., Ward, R. (2015). Mosaic epigenetic inheritance as a cause of early-onset colorectal cancer. JAMA Oncology, 1(7), 953-957. [More Information]
• Schaffer, A., Pearson, S., Dobbins, T., Er, C., Ward, R., Vajdic, C. (2015). Patterns of care and survival after a cancer of unknown primary (CUP) diagnosis: A population-based nested cohort study in Australian Government Department of Veterans' Affairs clients. Cancer Epidemiology, 39(4), 578-584. [More Information]
• Zarzour, P., Boelen, L., Luciani, F., Beck, D., Sakthianandeswaren, A., Mouradov, D., Sieber, O., Hawkins, N., Hesson, L., Ward, R., et al (2015). Single nucleotide polymorphism array profiling identifies distinct chromosomal aberration patterns across colorectal adenomas and carcinomas. Genes Chromosomes and Cancer, 54(5), 303-314. [More Information]
• Henry, C., Llamosas, E., Knipprath-Meszaros, A., Schoetzau, A., Obermann, E., Fuenfschilling, M., Caduff, R., Fink, D., Hacker, N., Ward, R., et al (2015). Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion. Oncotarget, 6(37), 40310-40326. [More Information]
• Jorissen, R., Christie, M., Mouradov, D., Sakthianandeswaren, A., Li, S., Love, C., Xu, Z., Molloy, P., Jones, I., Ward, R., et al (2015). Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer. British Journal of Cancer, 113(6), 979-988. [More Information]

2014

• Ward, R. (2014). A decade of promises in personalised cancer medicine: is the honeymoon over? Medical Journal of Australia, 200(3), 132-133. [More Information]
• Hesson, L., Sloane, M., Wong, J., Nunez, A., Srivastava, S., Ng, B., Hawkins, N., Bourke, M., Ward, R. (2014). Altered promoter nucleosome positioning is an early event in gene silencing. Epigenetics, 9(10), 1422-1430. [More Information]
• Vajdic, C., Er, C., Schaffer, A., Dobbins, T., Wyld, L., Meagher, N., Barrett, J., Ward, R., Pearson, S. (2014). An audit of cancer of unknown primary notifications: A cautionary tale for population health research using cancer registry data. Cancer Epidemiology, 38(4), 460-464. [More Information]
• Thompson, B., Spurdle, A., Plazzer, J., Greenblatt, M., Akagi, K., Al-Mulla, F., Bapat, B., Bernstein, I., Capella, G., Ward, R., et al (2014). Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nature Genetics, 46(2), 107-115. [More Information]
• Xu, H., Yan, Y., Deb, S., Rangasamy, D., Germann, M., Malaterre, J., Eder, N., Ward, R., Hawkins, N., Tothill, R., McKay, M., et al (2014). Cohesin Rad21 Mediates Loss of Heterozygosity and Is Upregulated via Wnt Promoting Transcriptional Dysregulation in Gastrointestinal Tumors. Cell Reports, 9(5), 1781-1797. [More Information]
• Hesson, L., Ward, R. (2014). Discrimination of pseudogene and parental gene dna methylation using allelic bisulfite sequencing. Methods in Molecular Biology, 1167, 265-274. [More Information]
• Sloane, M., Wong, J., Perera, D., Nunez, A., Pimanda, J., Hawkins, N., Sieber, O., Bourke, M., Hesson, L., Ward, R. (2014). Epigenetic inactivation of the candidate tumor suppressor USP44 is a frequent and early event in colorectal neoplasia. Epigenetics, 9(8), 1092-1100. [More Information]
• Jacob, F., Hitchins, M., Fedier, A., Brennan, K., Nixdorf, S., Hacker, N., Ward, R., Heinzelmann-Schwarz, V. (2014). Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells. BMC Molecular Biology, 15(1). [More Information]
• Hillman, R., Garland, S., Gunathilake, M., Stevens, M., Kumaradevan, N., Lemech, C., Ward, R., Meagher, A., McHugh, L., Jin, F., et al (2014). Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers. International Journal of Cancer, 135(4), 996-1001. [More Information]
• Scott, G., Hettiaratchi, A., Salisbury, E., Ward, R., Hawkins, N. (2014). Institutional biobanking: an integral part of contemporary pathology practice. Pathology, 47(1), 4-6. [More Information]
• Wyld, L., Smith, S., Hawkins, N., Long, J., Ward, R. (2014). Introducing research initiatives into healthcare: What do doctors think? Biopreservation and Biobanking, 12(2), 91-98. [More Information]
• Vajdic, C., Stavrou, E., Ward, R., Falster, M., Pearson, S. (2014). Minimal excess risk of cancer and reduced risk of death from cancer in Australian Department of Veterans' Affairs clients: A record linkage study. Australian and New Zealand Journal of Public Health, 38(1), 30-34. [More Information]
• Sloane, M., Hesson, L., Nunez, A., Thompson, B., Ward, R. (2014). Nucleosome positioning is unaltered at MLH1 splice site mutations in cells derived from Lynch syndrome patients. Clinical Epigenetics, 6(1). [More Information]
• Deb, S., Xu, H., Tuynman, J., George, J., Yan, Y., Li, J., Ward, R., Mortensen, N., Hawkins, N., McKay, M., et al (2014). RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas. British Journal of Cancer, 110(6), 1606-1613. [More Information]
• Frayling, I., Ward, R. (2014). Should we consider introducing systematic screening for lynch syndrome? Cancer Forum, 38(3), 187-190. [More Information]
• Chin, M., Ward, R. (2014). Targeting treatment for colorectal cancer: The EGFR antibody story. Cancer Forum, 38(1), 39-43. [More Information]
• Killick, E., Tymrakiewicz, M., Cieza-Borrella, C., Smith, P., Thompson, D., Pooley, K., Easton, D., Bancroft, E., Page, E., Leongamornlert, D., Ward, R., et al (2014). Telomere Length Shows No Association with BRCA1 and BRCA2 Mutation Statu. PloS One, 9(1), e86659. [More Information]
• Patil, V., Ward, R., Hesson, L. (2014). The evidence for functional non-CpG methylation in mammalian cells. Epigenetics, 9(6), 823-828. [More Information]
• Hesson, L., Ward, R. (2014). The importance of distinguishing pseudogenes from parental genes. Clinical Epigenetics, 6(1), 90. [More Information]
• Kwok, C., Vogelaar, I., van Zelst-Stams, W., Mensenkamp, A., Ligtenberg, M., Rapkins, R., Ward, R., Chun, N., Ford, J., et al (2014). The MLH1 c.-27C>A and c.85G>T variants are linked to dominantly inherited MLH1 epimutation and are borne on a European ancestral haplotype. European Journal of Human Genetics, 22(5), 617-624. [More Information]
• Ford, C., Punnia-Moorthy, G., Henry, C., Llamosas, E., Nixdorf, S., Olivier, J., Caduff, R., Ward, R., Heinzelmann-Schwarz, V. (2014). The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Gynecologic Oncology, 134(2), 338-345. [More Information]
• Dewhurst, S., McGranahan, N., Burrell, R., Rowan, A., Gronroos, E., Endesfelder, D., Joshi, T., Mouradov, D., Gibbs, P., Ward, R. (2014). Tolerance of whole- genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discovery, 4(2), 175-185. [More Information]

2013

• Metz, A., Bourke, M., Moss, A., Ashraf, D., Zarzour, P., Hawkins, N., Ward, R., Hesson, L. (2013). A correlation of the endoscopic characteristics of colonic laterally spreading tumours with genetic alterations. European journal of gastroenterology & hepatology, 25(3), 319-326. [More Information]
• Christie, M., Jorissen, R., Mouradov, D., Sakthianandeswaren, A., Li, S., Day, F., Tsui, C., Lipton, L., Desai, J., Ward, R., et al (2013). Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/?-catenin signalling thresholds for tumourigenesis. Oncogene, 32(39), 4675-4682. [More Information]
• Zarzour, P., Hesson, L., Ward, R. (2013). Establishing the clinical utility of epigenetic markers in cancer: Many challenges ahead. Epigenomics, 5(5), 513-523. [More Information]
• Ward, R., Dobbins, T., Lindor, N., Rapkins, R., Hitchins, M. (2013). Identification of constitutional MLH1 epimutations and promoter variants in colorectal cancer patients from the Colon Cancer Family Registry. Genetics in Medicine, 15(1), 25-35. [More Information]
• Liu, J., Hesson, L., Ward, R. (2013). Liquid Chromatography Tandem Mass Spectrometry for the Measurement of Global DNA Methylation and Hydroxymethylation. Journal of Proteomics & Bioinformatics, S2, 1-6. [More Information]
• Day, F., Jorissen, R., Lipton, L., Mouradov, D., Sakthianandeswaren, A., Christie, M., Li, S., Tsui, C., Tie, J., Ward, R. (2013). PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in Colorectal cancer. Clinical Cancer Research, 19(12), 3285-3296. [More Information]
• Ward, R., Hicks, S., Hawkins, N. (2013). Population-based molecular screening for lynch syndrome: Implications for personalized medicine. Journal of Clinical Oncology, 31(20), 2554-2562. [More Information]
• Webster, L., Provan, P., Graham, J., Byth Wilson, K., Walker, R., Davis, S., Salisbury, E., Morey, A., Ward, R., Hawkins, N., Clarke, C., Balleine, R., et al (2013). Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33. Pathology, 45(7), 629-636. [More Information]
• Jin, Q., Han, H., Hu, X., Li, X., Zhu, C., Ho, S., Ward, R., Zhang, A. (2013). Quantifying Species Diversity with a DNA Barcoding-Based Method: Tibetan Moth Species (Noctuidae) on the Qinghai-Tibetan Plateau. PloS One, 8(5), 1-13. [More Information]
• Hesson, L., Patil, V., Sloane, M., Nunez, A., Liu, J., Pimanda, J., Ward, R. (2013). Reassembly of Nucleosomes at the MLH1 Promoter Initiates Resilencing Following Decitabine Exposure. PLoS Genetics, 9(7). [More Information]
• Fleming, N., Jorissen, R., Mouradov, D., Christie, M., Sakthianandeswaren, A., Palmieri, M., Day, F., Li, S., Tsui, C., Ward, R. (2013). SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Research, 73(2), 725-735. [More Information]
• Mouradov, D., Domingo, E., Gibbs, P., Jorissen, R., Li, S., Soo, P., Lipton, L., Desai, J., Danielsen, H., Ward, R., et al (2013). Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. American Journal of Gastroenterology, 108(11), 1785-1793. [More Information]
• Ford, C., Ma, S., Quadir, A., Ward, R. (2013). The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis. International Journal of Cancer, 133(4), 779-787. [More Information]
• Ford, C., Jary, E., Ma, S., Nixdorf, S., Heinzelmann-Schwarz, V., Ward, R. (2013). The Wnt Gatekeeper SFRP4 Modulates EMT, Cell Migration and Downstream Wnt Signalling in Serous Ovarian Cancer Cells. PloS One, 8(1). [More Information]
• Loh, Y., Hedditch, E., Baker, L., Jary, E., Ward, R., Ford, C. (2013). The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer, 13. [More Information]
• Lu, C., Srasuebkul, P., Drew, A., Chen, K., Ward, R., Pearson, S. (2013). Trastuzumab therapy in Australia: Which patients with HER2+ metastatic breast cancer are assessed for cardiac function? Breast, 22(4), 482-487. [More Information]
• Langton, J., Pesa, N., Rushton, S., Ward, R., Pearson, S. (2013). Uptake of a web-based oncology protocol system: how do cancer clinicians use eviQ cancer treatments online? BMC Cancer, 13, 1-9. [More Information]
• Mak, G., Ward, R., Shehabi, Y., Venkateswaran, R., Chin, M. (2013). Use of neostigmine in capecitabine-induced paralytic ileus. Tumori: a journal of experimental and clinical oncology, 99(5), e225-e228. [More Information]

2012

• Hesson, L., Packham, D., Pontzer, E., Funchain, P., Eng, C., Ward, R. (2012). A reinvestigation of somatic hypermethylation at the PTEN CpG island in cancer cell lines. Biological Procedures Online, 14(1). [More Information]
• Haywood, P., de Raad, J., van Gool, K., Haas, M., Gallego, G., Pearson, S., Faedo, M., Ward, R. (2012). Chemotherapy administration: Modelling the costs of alternative protocols. PharmacoEconomics, 30(12), 1173-1186. [More Information]
• Vajdic, C., Meagher, N., Hicks, S., Faedo, M., Ward, R., Pearson, S. (2012). Governance approval for multisite, non-interventional research: what can Harmonisation of Multi-Centre Ethical Review learn from the New South Wales experience? Internal Medicine Journal, 42(2), 127-131. [More Information]
• Hains, I., Ward, R., Pearson, S. (2012). Implementing a web-based oncology protocol system in Australia: evaluation of the first 3 years of operation. Internal Medicine Journal, 42(1), 57-64. [More Information]
• Sigglekow, N., Pangon, L., Brummer, T., Molloy, M., Hawkins, N., Ward, R., Musgrove, E., Kohonen-Corish, M. (2012). Mutated in colorectal cancer protein modulates the NF?B pathway. Anticancer Research, 32(1), 73-79.
• Stavrou, E., Ward, R., Pearson, S. (2012). Oesophagectomy rates and post-resection outcomes in patients with cancer of the oesophagus and gastro-oesophageal junction: a population-based study using linked health administrative linked data. BMC Health Services Research, 12(1), 1-10. [More Information]
• Campone, M., Bondarenko, I., Brincat, S., Hotko, Y., Munster, P., Chmielowska, E., Fumoleau, P., Ward, R., Bardy-Bouxin, N., et al (2012). Phase II study of single-agent bosutinib, a src/abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Annals of Oncology, 23(3), 610-617. [More Information]
• Lu, C., Srasuebkul, P., Drew, A., Ward, R., Pearson, S. (2012). Positive spillover effects of prescribing requirements: Increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer. Internal Medicine Journal, 42(11), 1229-1235. [More Information]
• Liu, J., Hesson, L., Meagher, A., Bourke, M., Hawkins, N., Rand, K., Molloy, P., Pimanda, J., Ward, R. (2012). Relative distribution of folate species is associated with global DNA methylation in human colorectal mucosa. Cancer Prevention Research, 5(7), 921-929. [More Information]

2011

• Lu, C., Srasuebkul, P., Ward, R., Pearson, S. (2011). Cardiotoxic Cancer Therapies in Australia: Which Patients are Assessed for Cardiac Function? International Society of Pharmacoepidemiology Meeting 2011, Chicago, IL.
• Goel, A., Nguyen, T., Leung, H., Nagasaka, T., Rhees, J., Hotchkiss, E., Arnold, M., Banerji, P., Koi, M., Ward, R., et al (2011). De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one. International Journal of Cancer, 128(4), 869-878. [More Information]
• Hitchins, M., Rapkins, R., Kwok, C., Srivastava, S., Wong, J., Khachigian, L., Polly, P., Goldblatt, J., Ward, R. (2011). Dominantly Inherited Constitutional Epigenetic Silencing of MLH1 in a Cancer-Affected Family Is Linked to a Single Nucleotide Variant within the 5'UTR. Cancer Cell, 20(2), 200-213. [More Information]
• Lu, C., Srasuebkul, P., Drew, A., Ward, R., Pearson, S. (2011). Spillover effects of prescribing restrictions for trastuzumab in Australia. Third International Conference for Improving Use of Medicines.
• Harris, C., Ward, R., Dobbins, T., Drew, A., Pearson, S. (2011). The efficacy of HER2 targeted agents in metastatic breast cancer: A meta-analysis. Annals of Oncology, 22(6), 1308-1317. [More Information]
• Pearson, S., Srasuebkul, P., Dobbins, T., Lu, C., Ward, R. (2011). The Impact of Evidence-Based Subsidy Restrictions on Lapatinib Use and Outcomes. International Society of Pharmacoepidemiology Meeting 2011, Chicago, IL.
• Pearson, S., Srasuebkul, P., Lu, C., Dobbins, T., Ward, R. (2011). The impact of evidence-based subsidy restrictions on prescriber behaviour and patient outcomes: A case study of lapatinib for the treatment of HER2+ metastatic breast cancer. Third International Conference for Improving Use of Medicines.
• Langton, J., Drew, A., Mellish, L., Olivier, J., Ward, R., Pearson, S. (2011). The quality of web-based oncology guidelines and protocols: how do international sites stack up? British Journal of Cancer, 105(8), 1166-1172. [More Information]

2010

• Vajdic, C., Meagher, N., Hicks, S., Faedo, M., Ward, R., Pearson, S. (2010), Governance approval for multisite, non-interventional research: what can HoMER learn from the NSW experience?.
• Vajdic, C., Meagher, N., Hicks, S., Faedo, M., Ward, R., Pearson, S. (2010). Governance approval for multisite, non-interventional research: what can HoMER learn from the NSW experience? Sydney Cancer Conference 2010, Sydney, Australia: University of Sydney.
• Harris, C., Pearson, S., Dobbins, T., Drew, A., Ward, R. (2010). HER2 targeted agents improve overall survival in HER2+ metastatic breast cancer (MBC): A meta-analysis. Medical Oncology Group of Australia Annual Scientific Meeting, Sydney, Australia: Wiley-Blackwell Publishing Asia Pty Ltd.
• Pearson, S., Srasuebkul, P., Stavrou, E., Ward, R., Dobbins, T. (2010). New HER2 therapies for metastatic breast cancer: Are prescribers the obstacle to access in Australia? International Society of Pharmacoepidemiology 5th Asian Meeting, Tokyo.
• de Raad, J., van Gool, K., Haas, M., Haywood, P., Faedo, M., Gallego, G., Pearson, S., Ward, R. (2010). Nursing takes time: workload associated with administering cancer protocols. Clinical Journal of Oncology Nursing, 14(6), 735-741. [More Information]
• Pearson, S., Chin, M., Faedo, M., Ward, R. (2010). Rationale for treatment durations of targeted cancer agents. The Lancet Oncology, 11(12), 1113-1115. [More Information]
• Srasuebkul, P., Pearson, S., Harris, C., Ward, R., Dobbins, T. (2010). The impact of oestrogen receptor (ER) status on overall survival of metastatic breast cancer patients receiving trastuzumab in Australia. 16th Annual Japanese Society for Pharmacoepidemiology Meeting and the 5th Annual Asian Conference on Pharmacoepidemiology, Japan: ACPE.
• Trainer, A., Lewis, C., Tucker, K., Meiser, B., Friedlander, M., Ward, R. (2010). The role of BRCA mutation testing in determining breast cancer therapy. Nature Reviews Clinical Oncology, 7(12), 708-715. [More Information]
• Pearson, S., Srasuebkul, P., Harris, C., Ward, R., Dobbins, T. (2010). Trastuzumab (T) treatment outcomes according to concomitant chemotherapy regimen: Overall survival (OS) of HER2+ metastatic breast cancer (MBC) patients. 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Brighton, UK: International Society for Pharmacoepidemiology.
• Srasuebkul, P., Pearson, S., Harris, C., Ward, R., Dobbins, T. (2010). Trastuzumab (T) treatment outcomes according to estrogen receptor (ER) status: Overall survival (OS) of HER2+ metastatic breast cancer (MBC) patients. Sydney Cancer Conference 2010, Sydney, Australia: University of Sydney.

2009

• Hitchins, M., Ward, R. (2009). Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. Journal of Medical Genetics, 46(12), 793-802. [More Information]
• Faedo, M., Pearson, S., Bastick, P., van Gool, K., Haywood, P., Haas, M., Ward, R. (2009). Elements of cancer care study: Tracking resource utilisation and costs in a cohort of NSW cancer patients. 6th Health Services and Policy Research Conference, Brisbane: Faculty of Health Sciences, University of Sydney.
• Hawkins, N., Lee, J., Wong, J., Kwok, C., Ward, R., Hitchins, M. (2009). MGMT methylation is associated primarily with the germline CT SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Modern Pathology, 22(12), 1588-1599. [More Information]
• Cooper, W., Hesson, L., Matallanas, D., Dallol, A., von Kriegsheim, A., Ward, R., Kolch, W., Latif, F. (2009). RASSF2 associates with and stabilizes the proapoptotic kinase MST2. Oncogene, 28(33), 2988-2998. [More Information]
• Carr, N., Mahajan, H., Tan, K., Hawkins, N., Ward, R. (2009). Serrated and non-serrated polyps of the colorectum: Their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma. Journal of Clinical Pathology, 62(6), 516-518. [More Information]
• Hains, I., Fuller, J., Ward, R., Pearson, S. (2009). Standardizing care in medical oncology: Are web-based systems the answer? Cancer, 115(23), 5579-5588. [More Information]
• Pearson, S., Chin, M., Ward, R. (2009). The financially tolerable dose: A new concept in clinical trial design? 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, USA: International Society for Pharmacoepidemiology.
• Pearson, S., Faedo, M., van Gool, K., Haas, M., Ward, R. (2009). Using routinely collected health data to inform economic models of cancer care. 6th Health Services and Policy Research Conference, Brisbane: Faculty of Health Sciences, University of Sydney.

2008

• Hains, I., Bichel-Findlay, J., Rushton, S., Booth, A., Ward, R., Pearson, S. (2008). Barriers to using web-based chemotherapy protocols in Australian hospitals - The nurse perspective. National Medicines Symposium 2008, Canberra: Pharmaceutical Health and Rational Use of Medicines Committee.
• Ringland, C., Pearson, S., Ward, R. (2008). Cardiovascular medicine use in women receiving trastuzumab for HER-2 positive metastatic breast cancer. Sydney Cancer Conference 2008 (SCC2008), Sydney: University of Sydney.
• Cheong, L., Ward, R., Pearson, S. (2008). Dosing guidelines for cytotoxic cancer chemotherapy: Theory versus reality. National Medicines Symposium 2008, Canberra: Pharmaceutical Health and Rational Use of Medicines Committee.
• Hains, I., Ward, R., Pearson, S. (2008). Evaluating CI-SCaT use in NSW hospitals. Cancer Institute NSW Cancer Services and Education Research Meeting 2008, Sydney: Cancer Institute NSW.
• Pearson, S., Ringland, C., Ward, R. (2008). Lessons learnt from an evaluation of The Herceptin National Access Program for metastatic breast cancer. Sydney Cancer Conference 2008 (SCC2008), Sydney: University of Sydney.
• Pearson, S., Ringland, C., Ward, R. (2008). Off-label trastuzumab use in Australia: Evidence from the national Herceptin Program for HER-2 positive metastatic breast cancer. 24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management 2008, Copenhagen, Denmark: International Society for Pharmacoepidemiology.
• Webster, L., Lee, S., Ringland, C., Morey, A., Hanby, A., Morgan, G., Byth Wilson, K., Mote, P., Provan, P., Ellis, I., Lamoury, G., Clarke, C., Balleine, R., et al (2008). Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification. Clinical Cancer Research, 14(20), 6625-6633. [More Information]
• Weber, M., Banks, E., Ward, R., Sitas, F. (2008). Population characteristics related to colorectal cancer testing in New South Wales, Australia: results from the 45 and Up Study cohort. Journal of Medical Screening, 15(3), 137-142. [More Information]
• Bastick, P., Faedo, M., Van Gool, K., Pearson, S., Haas, M., Ward, R. (2008). Rationing high cost cancer medicines: Building the evidence base to support local decision makers. MOGA/FRO/NZSO/NZACS Joint Scientific Meeting, Christchurch: Wiley.
• Ringland, C., Pearson, S., Ward, R. (2008). Survival of women treated with trastuzumab for HER-2 positive metastatic breast cancer: Estimating outcomes in clinical practice with administrative data. 24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management 2008, Copenhagen, Denmark: International Society for Pharmacoepidemiology.
• Hains, I., Bichel-Findlay, J., Rushton, S., Ward, R., Pearson, S. (2008). The use of web-based chemotherapy protocols in Australian hospitals: Barriers to their uptake - The nurse perspective. Cancer Nurses Society of Australia (CNSA) 11th Winter Congress 2008, Gold Coast, Australia: Cancer Nurses Society of Australia.
• Faedo, M., van Gool, K., Pearson, S., Haas, M., Ward, R. (2008). Using clinical and economic evidence to inform local decision making in cancer care. National Medicines Symposium 2008, Canberra: Pharmaceutical Health and Rational Use of Medicines Committee.
• Hains, I., Bichel-Findlay, J., Rushton, S., Booth, A., Ward, R., Pearson, S. (2008). Web-based chemotherapy protocols - A help or hindrance? National Medicines Symposium 2008, Canberra: Pharmaceutical Health and Rational Use of Medicines Committee.
• Hains, I., Rushton, S., Bichel-Findlay, J., Booth, A., Ward, R., Pearson, S. (2008). Web-based chemotherapy protocols - friend or foe? Centre for Health Informatics Seminar Series 2008, Sydney: Centre for Health Informatics.

2007

• Wong, J., Hawkins, N., Ward, R. (2007). Colorectal cancer: A model for epigenetic tumorigenesis. Gut, 56(1), 140-148. [More Information]
• Hitchins, M., Lin, V., Buckle, A., Cheong, K., Halani, N., Ku, S., Kwok, C., Packham, D., Suter, C., Ward, R. (2007). Epigenetic inactivation of a cluster of genes flanking MLH1 in microsatellite-unstable colorectal cancer. Cancer Research, 67(19), 9107-9116. [More Information]
• More, H., Humar, B., Weber, W., Ward, R., Christian, A., Lintott, C., Graziano, F., Ruzzo, A., Acosta, E., Boman, B., et al (2007). Identification of seven novel germline mutations in the human E-cadherin (CDH1) gene. Human Mutation, 28(2), 1-9. [More Information]
• Hitchins, M., Wong, J., Suthers, G., Suter, C., Martin, D., Hawkins, N., Ward, R. (2007). Inheritance of a cancer-associated MLH1 germ-line epimutation. New England Journal of Medicine, 356(7), 697-705. [More Information]
• Pearson, S., Ringland, C., Ward, R. (2007), Making best use of secondary data sources for pharmaceutical policy evaluation in Australia: Hopes and realities.
• Ioannidis, J., Ahmed, T., Awasthi, S., Clarfield, A., Dandona, L., Clark, J., Howe, A., Lozano, J., Li, Y., Madani, H., et al (2007). Open letter to the leader of academic medicine. BMJ, 334(7586), 191-193. [More Information]
• Pearson, S., Ringland, C., Ward, R. (2007). Trastuzumab and metastatic breast cancer: Trastuzumab use in Australia - Monitoring the effect of an expensive medicine access program. Journal of Clinical Oncology, 25(24), 3688-3693. [More Information]
• Pearson, S., Ringland, C., Ward, R. (2007). Use of Trastuzumab for metastatic breast cancer in Australia: interpreting findings from a cohort of 1,469 women on a national access program versus 41 women treated by two medical oncologists. Journal of Clinical Oncology, 25(35), 5663-5664. [More Information]
• Pearson, S., Ringland, C., Ward, R. (2007). Using administrative data sources for Australian pharmaceutical policy evaluation: potential and realities. St Vincent's Hospital Meeting 2007, Sydney: St Vincent's Hospital.

2006

• Tan, E., Stark, H., Lowinger, J., Ringland, C., Ward, R., Pearson, S. (2006). Information Sources used by New South Wales cancer clinicians: a qualitative study. Internal Medicine Journal, 36(11), 711-717. [More Information]
• Brown, D., Stephan, C., Ward, R., Law, M., Hunter, M., Bauskin, A., Amin, J., Jung, K., Diamandis, E., et al (2006). Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clinical Cancer Research, 12(1), 89-96. [More Information]
• Gazarian, M., Kelly, M., McPhee, J., Graudins, L., Ward, R., Campbell, T. (2006). Off-label use of medicines: consensus recommendations for evaluating appropriateness. Medical Journal of Australia, 185(10), 544-548. [More Information]
• Van Gool, K., Gallego, G., Haas, M., Hall, J., Ward, R., Links, M., Stewart, B., Board, N., Pearson, S. (2006). Reporting economic evidence in cancer protocols: What decision makers really want. Health Technology Assessment International (HTAi 2006), Adelaide: University of Adelaide.
• Johnson, K., Ringland, C., Stokes, B., Anthony, D., Freemantle, N., Irs, A., Hill, S., Ward, R. (2006). Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. The Lancet Oncology, 7(9), 741-746. [More Information]

2005

• Tothill, R., Kowalczyk, A., Rischin, D., Bousioutas, A., Haviv, I., van Laar, R., Waring, P., Zalcberg, J., Ward, R., et al (2005). An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Research, 65(10), 4031-4040. [More Information]

2004

• Suter, C., Martin, D., Ward, R. (2004). Germline epimutation of MLH1 in individuals with multiple cancers. Nature Genetics, 36(5), 497-501. [More Information]
• Suter, C., Martin, D., Ward, R. (2004). Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue. International Journal of Colorectal Disease, 19(2), 95-101. [More Information]
• Morgan, G., Ward, R., Barton, M. (2004). The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clinical Oncology, 16(8), 549-560. [More Information]

2003

• Ward, R., Cheong, K., Ku, S., Meagher, A., O’Connor, T., Hawkins, N. (2003). Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. Journal of Clinical Oncology, 21(20), 3729-3736. [More Information]
• Bariol, C., Hawkins, N., Turner, J., Meagher, A., Williams, D., Ward, R. (2003). Histopathological and clinical evaluation of serrated adenomas of the colon and rectum. Modern Pathology, 16(5), 417-423. [More Information]
• Grieu, F., Malaney, S., Ward, R., Joseph, D., Iacopetta, B. (2003). Lack of Association between CCND1 G870A Polymorphism and the Risk of Breast and Colorectal Cancers. Anticancer Research, 23(5 B), 4257-4259.
• Welsh, J., Sapinoso, L., Kern, S., Brown, D., Liu, T., Bauskin, A., Ward, R., Hawkins, N., Quinn, D., et al (2003). Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proceedings of the National Academy of Sciences of the United States of America, 100(6), 3410-3415. [More Information]
• Brown, D., Ward, R., Buckhaults, P., Liu, T., Romans, K., Hawkins, N., Bauskin, A., Kinzler, K., Vogelstein, B., Breit, S. (2003). MIC-1 serum level and genotype: Associations with progress and prognosis of colorectal carcinoma. Clinical Cancer Research, 9(7), 2642-2650.
• Bariol, C., Suter, C., Cheong, K., Ku, S., Meagher, A., Hawkins, N., Ward, R. (2003). The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. American Journal of Pathology, 162(4), 1361-1371. [More Information]

2002

• Hawkins, N., Norrie, M., Cheong, K., Mokany, E., Ku, S., Meagher, A., O’Connor, T., Ward, R. (2002). CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology, 122(5), 1376-1387. [More Information]
• Tomlinson, I., Halford, S., Aaltonen, L., Hawkins, N., Ward, R. (2002). Does MSI-low exist? Journal of Pathology, 197(1), 6-13. [More Information]
• Halford, S., Sasieni, P., Rowan, A., Wasan, H., Bodmer, W., Talbot, I., Hawkins, N., Ward, R., Tomlinson, I. (2002). Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. Cancer Research, 62(1), 53-57.
• Humar, B., Toro, T., Graziano, F., Muller, H., Dobbie, Z., Yang, H., Eng, C., Hampel, H., Gilbert, D., Ward, R., et al (2002). Novel germline CDH1 mutations in hereditary diffuse gastric cancer families. Human Mutation, 19(5), 518-525. [More Information]
• Hawkins, N., Bariol, C., Ward, R. (2002). The serrated neoplasia pathway. Pathology, 34(6), 548-555.

2001

• Yip, Y., Ward, R. (2001). Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunology, Immunotherapy, 50(11), 569-587. [More Information]
• Yip, Y., Smith, G., Koch, J., Dubel, S., Ward, R. (2001). Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: Implications for vaccine design. Journal of Immunology, 166(8), 5271-5278. [More Information]
• Andreyev, H., Norman, A., Cunningham, D., Oates, J., Dix, B., Iacopetta, B., Young, J., Walsh, T., Ward, R., et al (2001). Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. British Journal of Cancer, 85(5), 692-696. [More Information]
• Ward, R., Meagher, A., Tomlinson, I., O’Connor, T., Norrie, M., Wu, R., Hawkins, N. (2001). Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut, 48(6), 821-829. [More Information]
• Hawkins, N., Tomlinson, I., Meagher, A., Ward, R. (2001). Microsatellite-stable diploid carcinoma: A biologically distinct and aggressive subset of sporadic colorectal cancer. British Journal of Cancer, 84(2), 232-236. [More Information]
• Hawkins, N., Ward, R. (2001). Sporadic colerectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. Journal of the National Cancer Institute, 93(17), 1307-1313. [More Information]

2000

• Hawkins, N., Gorman, P., Tomlinson, I., Bullpitt, P., Ward, R. (2000). Colorectal carcinomas arising in the hyperplastic polyposis syndrome progress through the chromosomal instability pathway. American Journal of Pathology, 157(2), 385-392. [More Information]

1999

• Ward, R., Hawkins, N., Coomber, D., Disis, M. (1999). Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. Human Immunology, 60(6), 510-515. [More Information]

1998

• Ward, R., Hawkins, N., O'Grady, R., Sheehan, C., O’Connor, T., Impey, H., Roberts, N., Fuery, C., Todd, A. (1998). Restriction endonuclease-mediated selective polymerase chain reaction: A novel assay for the detection of K-ras mutations in clinical samples. American Journal of Pathology, 153(2), 373-379. [More Information]
• Lord,, R., Law, M., Ward, R., Giles, G., Thomas, R., Thursfield, V. (1998). Rising incidence of oesophageal adenocarcinoma in men in Australia. Journal of Gastroenterology and Hepatology, 13(4), 356-362. [More Information]

1997

• Ward, R., Todd, A., Santiago, F., O’Connor, T., Hawkins, N. (1997). Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. Cancer, 79(6), 1106-1113.

1993

• Ward, R., Morgan, G., Dalley, D., Kelly, P. (1993). Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Journal of Bone and Mineral Research, 22(2), 87-94. [More Information]

1992

• Smith, G., Ward, R., McGuigan, L., Rajkovic, A., Scott, K. (1992). Measurement of human phospholipase a in arthritis plasma using a newly developed sandwich elisa. British Journal of Rheumatology, 31(3), 175-178. [More Information]

1990

• Kelly, P., Atkinson, K., Ward, R., Sambrook, P., Biggs, J., Eisman, J. (1990). Reduced bone mineral density in men and women with allogeneic bone marrow transplantation. Transplantation, 50(5), 881-883. [More Information]